Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca’s Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission.

Read More »

Lynparza stalls pancreatic cancer in patients with BRCA mutations: study

AstraZeneca and Merck & Co.’s Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go nearly twice as long without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial.

Read More »

Breakthrough in Pancreatic Cancer Research Could Lead to New Treatments

Researchers with the NYU School of Medicine and the University of Michigan identified a gene called ATDC that is necessary for the development of pancreatic cancer.

Read More »

AbbVie Cuts 178 Stemcentrx Employees Months After Rova-T Failure

AbbVie is slashing 178 jobs from the company’s Stemcentrx subsidiary in South San Francisco.

Read More »

Celgene’s Abraxane Fails to Hit Mark in Phase III Pancreatic Cancer Study

Celgene’s Abraxane failed to hit endpoints of improving disease-free survival in a late-stage study of pancreatic cancer patients.

Read More »

Lynparza meets main goal in pancreatic cancer study

AstraZeneca Plc said the British drugmaker’s cancer drug being jointly developed with U.S.-based Merck & Co. met the primary goal in a late-stage study for a rare type of pancreatic cancer.

Read More »

Imbruvica fails to meet pancreatic cancer study goal

AbbVie Inc.’s blockbuster cancer treatment Imbruvica in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.

Read More »

A Glimpse into the Pancreatic Cancer Pipeline

The passing of singing great Aretha Franklin has focused attention on pancreatic cancer. Franklin, 76, succumbed to a neuroendocrine tumor of the pancreas. According to the National Cancer Institute, pancreatic cancer is relatively rare with about 55,440 cases diagnosed annually, representing about 3.2 percent of new cancer cases.

Read More »

BioLineRx, Merck Expand Immuno-Oncology Collaboration in Pancreatic Cancer

BioLineRx Ltd. announced the expansion of its immuno-oncology collaboration with Merck & Co. Inc. for the support of a Phase 2a program investigating BioLineRx’s BL-8040 in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) in patients with metastatic pancreatic cancer.

Read More »

Landmark Study Shows Precision Medicine Benefits Pancreatic Cancer Patients

A study published today by the Pancreatic Cancer Action Network, Perthera Inc., and colleagues in the AACR journal Clinical Cancer Research found for the first time that precision medicine can improve outcomes and provide clinically meaningful information to pancreatic cancer patients.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom